Tesamorelin and the GH Axis in Preclinical Studies

Tesamorelin is a synthetic analogue of growth hormone-releasing hormone (GHRH) consisting of the full 44-amino acid sequence of human GHRH with a stabilizing modification. A formulation of tesamorelin has received FDA approval for a specific clinical indication, providing a body of published clinical and preclinical literature.

Mechanisms of Action

Tesamorelin binds to GHRH receptors on pituitary somatotroph cells, stimulating endogenous growth hormone secretion in a physiologically pulsatile manner. Unlike exogenous GH administration, it preserves the natural feedback regulation of the GH axis. A formulation of tesamorelin has received FDA approval for a specific clinical indication, providing a body of published clinical and preclinical data.

*For laboratory and research purposes only. Not for human or animal consumption.*

Disclaimer: The information provided in this article is for educational and informational purposes only. All compounds discussed are for laboratory and research purposes only. Not for human or animal consumption. No medical claims are made.